Merck submits modified niacin to FDA

Share this article:
Merck's Cordaptive, an extended-release niacin combined with a flushing inhibitor, has been filed for approval with the FDA, the firm said.

Cordaptive could represent Merck's latest entrée into the $18-billion market for cholesterol drugs. Its statin Zocor (simvastatin) went off patent last year, but another cholesterol-lowering drug Vytorin, which Merck co-markets with Schering-Plough, has sold well.

Drugs that raise HDL, or “good,” cholesterol are considered a new direction for treatment. Flushing is the only known side effect of niacin, and analysts believe a more tolerable form could be a significant advance.

Back in March, Lehman Bros. analyst Tony Butler told MM&M that Cordaptive, then known as MK-524A, could earn between $800 million and $1 billion “or substantially more, if the clinical outcomes suggests a mortality benefit.”

Merck expects to present Phase III data at next month's European Society of Cardiology meeting and in November at a gathering of the American Heart Association.

The drug is designed to be used alone or in combination with a statin. MK-524B, Merck's combination of Cordaptive plus simvastatin (Zocor), is in Phase III trials.

An FDA decision for Cordaptive is anticipated in the second quarter of 2008, Merck said in a statement yesterday. It also plans to file for approval outside the US.

Niaspan, a branded, extended-release form of niacin sold by Kos, had US sales of $473.8 million last year, a 24% increase over 2005. Kos was bought by Abbott Labs in 2006.

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.